Use of capsaicin receptor antagonists to treat symptoms of tear gas exposure

Abstract

Disclosed are diaryl piperazines and related compounds. These compounds are selective modulators of capsaicin receptors, including human capsaicin receptors, that are, therefore, useful in the treatment of a chronic and acute pain conditions, itch and urinary incontinence. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of the invention are also useful as probes for the localization of capsaicin receptors and as standards in assays for capsaicin receptor binding and capsaicin receptor mediated cation conductance. Methods of using the compounds in receptor localization studies are given.

1 - 237 . (canceled) 
     
     
         238 : A method of treating a mammal suffering from irritation due to exposure to tear gas, the method comprising administering to the mammal a therapeutic dose of a compound that is capsaicin receptor antagonist; wherein the therapeutic dose contains an amount of the compound that is effective to reduce severity of the irritation. 
     
     
         239 : The method of  claim 238  wherein the mammal is a human. 
     
     
         240 : The method of  claim 238  wherein the exposure is exposure of mucous membranes via eye contact or inhalation. 
     
     
         241 : The method of  claim 238  wherein the compound is administered in a pharmaceutical composition comprising a pharmaceutically acceptable carrier. 
     
     
         242 : A method of treating a mammal suffering from inflammatory or bronchoconstriction symptoms resulting from exposure to tear gas, the method comprising administering to the mammal a therapeutic dose of a compound that is capsaicin receptor antagonist; wherein the therapeutic dose contains an amount of the compound that is effective to reduce severity of the inflammatory or bronchoconstriction symptoms. 
     
     
         243 : The method of  claim 242  wherein the mammal is a human. 
     
     
         244 : The method of  claim 242  wherein the mammal is suffering from inflammatory symptoms and the therapeutic dose contains an amount of the compound that is effective to reduce severity of the inflammatory symptoms. 
     
     
         245 : The method of  claim 244  wherein the compound is administered in a pharmaceutical composition comprising a pharmaceutically acceptable carrier. 
     
     
         246 : The method of  claim 242  wherein the mammal is suffering from bronchoconstriction symptoms and the therapeutic dose contains an amount of the compound that is effective to reduce severity of the bronchoconstriction symptoms. 
     
     
         247 : The method of  claim 246  wherein the compound is administered in a pharmaceutical composition comprising a pharmaceutically acceptable carrier.